ClinicalTrials.Veeva

Menu

Adherence to Dolutegravir and Outcome (DOLUTECAPS)

C

Caen University Hospital

Status

Unknown

Conditions

HIV

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The main assumption is that the dolutegravir can get virologic suppression to suboptimal adherence levels (between 80 and 95%, and after treatment interruptions) where other molecules are not capable, due to their pharmacokinetic/pharmacodynamic (pardonnance).

While the investigators goal is not to compare molecules (study with one arm) in terms of forgiveness, the results of this cohort in terms of forgiveness could be compared to other cohorts available.

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • HIV-1
  • Age over 18 years
  • Information letter signed
  • ART (antiretroviral therapy) with at least 3 active molecules
  • Patients starting treatment with dolutegravir (naïve to antiretroviral treatment, switch, virologic failure)

Exclusion criteria

  • pregnant woman
  • HIV-2
  • Patient does not have responsibility for the observance of treatment (disorder of judgment, guardianship, institutionalization)
  • Patient receiving aid incompatible with compliance with the use of electronic pillbox

Trial contacts and locations

1

Loading...

Central trial contact

Jean Jacques PARIENTI, MD,PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems